Biocon & Voluntis inks pact for global partnership on digital therapeutics for insulins

Biocon Ltd on Tuesday announced that Biocon’s subsidiary, Biocon Biologics India Ltd and Voluntis have entered into a global collaboration agreement to develop and distribute innovative digital therapeutics in order to support people with diabetes on biologics therapy.

With this agreement, Biocon Biologics will become one of the first companies to offer insulins to type 2 diabetes patients after getting a clearance from United States Food and Drug Administration (USFDA).

It would have certification (CE) mark thereby indicating conformity of health, safety, and environmental protection standards. This medicine would be available across various markets worldwide.

Nowadays, the demand for at-home treatment and telemedicine solutions is significantly rising around the world, which majorly includes the use of insulins among diabetes patients.

In its FY20 annual report, Biocon Limited has stated that it aims to list its biosimilar unit, Biocon Biologics in the next two to three years, subject to market conditions.

In March 2019, the company had hived off its biosimilars division into a separate unit - Biocon Biologics. The subsidiary has its own dedicated infrastructure and manages the manufacturing, development, and commercialisation of its biosimilars’ segment.

Today, the stock of Biocon opened at Rs 431.90 and made an intraday high of Rs 433.30 during the early trade on BSE.